SPYGLASS PHARMA INC

SGPNASDAQ

🏆 #2087 by market capUS Equity

$24.82▼ $0.31 (−1.25%)

Market closed · at close

1h—

24h▼ 1.3%

7d▲ 4.8%

14d▲ 14.0%

30d▲ 24.8%

1y—

🏦Market Cap

$830M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Weak

Trading Snapshot

Day Range: $24.43 – $24.96
52-Week Range: $17.06 – $32.44
Volume: $3.27B
Avg Volume: $3.30B
Shares Outstanding: 33.4M
Next Earnings: Oct 17, 2026

Fundamentals Snapshot

Annual Revenue: $82M
Last Q Revenue: $19M
P/E Ratio: —
P/S Ratio: —
EPS (TTM): $-2.78
Dividend Yield: —

Why Investors Own SGP

✓High-growth profile — revenue up -7.4% YoY with expanding US Equity exposure.
✓Healthy economics — 26% gross margin and 12% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$82M▼ −6.3% YoY

Gross Margin (TTM)

26.1%▲ +3.8% YoY

Operating Income (TTM)

$14M▼ −6.3% YoY

Free Cash Flow (TTM)

$10M▼ −6.3% YoY

About SPYGLASS PHARMA INC

SpyGlass Pharma, Inc. is an advanced biopharmaceutical company dedicated to developing innovative therapeutic approaches for individuals suffering from chronic eye conditions. Its flagship investigational product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), is engineered for implantation during standard cataract removal procedures with the aim of reducing elevated intraocular pressure (IOP) in patients afflicted with either open-angle glaucoma (OAG) or ocular hypertension (OHT). Co-founded in January 2019 by Malik Y. Kahook and Glenn Sussman, the company maintains its headquarters in Aliso Viejo, CA.

🦦